Why Drug Developers Have a Growing Interest in Targeting Mitochondria

Episode Summary

Executive Summary: Navdeep Shandell argues mitochondria are far more than cellular powerhouses: they generate ATP and metabolites, but also act as signaling organelles that influence immunity, cancer, inflammation, aging, diabetes, and neurodegeneration. He says the field needs deeper basic science before broad drug development can succeed, and more cross-disease collaboration and dedicated funding infrastructure.

Main Topics: Mitochondria as signaling organelles (Priority: 5/5): Shandell explains the modern view of mitochondria as active signaling hubs that help cells maintain homeostasis by releasing ATP, metabolites, hydrogen peroxide, and mitochondrial nucleic acids that affect immune and stress pathways. Mitochondria and cancer biology (Priority: 5/5): He argues most tumors have healthy mitochondria and depend on mitochondrial respiration for growth and metastasis; inhibiting respiration can shrink tumors in models, but clinical targeting remains difficult. Mitochondria, inflammation, and immunity (Priority: 4/5): Mitochondrial DNA/RNA can escape into the cytosol and activate innate immune sensors such as cGAS-STING and MAVS, driving interferon and inflammatory signaling. Disease links in neurodegeneration and diabetes (Priority: 4/5): He discusses stronger evidence in Parkinson’s disease and type 2 diabetes, but emphasizes that mitochondrial dysfunction may be cause or consequence and the exact mechanism remains uncertain. Aging and hormesis (Priority: 4/5): Shandell is skeptical that aging is simply caused by declining mitochondrial energy output; he suggests low-level stress signaling, DNA release, or mild inhibition may be more relevant than boosting mitochondria. Drug development and translational challenges (Priority: 5/5): He says the field has moved too quickly from discovery to engineering and trials. Metformin is cited as a cautionary example because transporter biology likely made broad trials fail. Need for cross-disciplinary collaboration and dedicated funding (Priority: 5/5): He calls for a mitochondrial-focused funding home or institute to unify expertise across cancer, neurology, metabolism, and inflammation rather than forcing researchers into disease silos.

Key Arguments: Mitochondria should be understood as signaling organelles, not just energy factories; they actively regulate cellular homeostasis and disease responses. Hydrogen peroxide (H2O2) is not purely harmful; at physiologic levels it functions as a beneficial signaling molecule, whereas lipid peroxides can drive ferroptosis and tissue damage. Mitochondrial DNA and RNA can serve as danger signals when released into the cytosol, activating cGAS-STING/MAVS pathways and type I interferons. In cancer, the old Warburg idea that tumor mitochondria are broadly dysfunctional is outdated; most tumors have functional mitochondria and may rely on respiration for growth and metastasis. Metformin’s failure in phase 3 cancer trials likely reflects poor patient stratification, since only cells with the right transporters take up the drug. For Parkinson’s disease, evidence is stronger because environmental toxins impair the respiratory chain and mutations in pink1/parkin affect mitochondrial quality control. For type 2 diabetes, impaired muscle mitochondrial function may contribute to poor glucose and fat oxidation, but the exact nature of dysfunction is still unclear. Aging should not be reduced to a simple loss of mitochondrial capacity; excess reserve means cells may still function despite reduced maximal mitochondrial output. The field needs more fundamental biology before broad therapeutic claims can be validated, especially outside cancer. Research is hampered by disease-specific funding structures; mitochondria-centered science would better support shared methods and cross-disease learning.

Data Points: Mitochondrial genes: 37 - He notes mitochondria retained 37 genes from their bacterial ancestor. Lurie Prize year: 2023 - Shandell was named a co-recipient of the 2023 Lurie Prize in Biomedical Sciences. Warburg discovery era: 1920s - He references Otto Warburg’s observations of tumor lactate production in the 1920s. Nobel Prize year for Warburg: 1931 - Warburg received the Nobel Prize for the enzyme that uses oxygen in cells. Clinical-trial timeline for GLP-1 drugs: ~40 years - He uses semaglutide-class drugs as an example of how long basic science to medicine can take. Immunotherapy timeline: ~30 years - He cites the long gap from foundational PD-1 research in the 1980s to modern clinical benefit. COVID mRNA vaccine timeline: late 1980s to pandemic era - He points to the long development arc of lipid nanoparticle-delivered RNA/DNA platforms. Cancer mutation frequency in mitochondrial proteins: <1% - He says rare mitochondrial protein mutations occur in only a small fraction of cancers.

Pivotal Quotes: ""Mitochondria have evolved from being not only powerhouses, but to being signaling organelles."" — Navdeep Shandell: Defines the podcast’s central thesis about the organelle’s expanded role. ""We think that metformin is a mitochondrial complex. One weak inhibitor gets into only a few tissues... the so-called anti-aging effects of metformin... might be because it's a mild respiratory chain inhibitor, a mild mitochondrial toxin."" — Navdeep Shandell: Explains why mild mitochondrial inhibition may be beneficial and why metformin may not be a straightforward anti-cancer or anti-aging drug. ""We, we've had the worst luck, Danny, I think in the sense that everybody agrees is very important, but then there's no home for it."" — Navdeep Shandell: Describes the lack of a dedicated institutional/funding home for mitochondrial research.

Implications: Mitochondria are emerging as a shared mechanism across major diseases, but translation will depend on better basic biology, disease-specific targeting, and cross-disciplinary funding. Broad one-size-fits-all therapies are unlikely to work.